Advances and challenges in mucosal adjuvant technology

Vaccine

Volumn 33, Issue 21, 2015, Pages 2399-2405

  Newsted, Daniel ^a   Fallahi, Firouzeh ^b   Golshani, Ashkan ^c   Azizi, Ali ^d,e  

^a MCMASTER UNIVERSITY   (Canada)

^b HEALTH CANADA   (Canada)

^c CARLETON UNIVERSITY   (Canada)

^d UNIVERSITY OF OTTAWA   (Canada)

^e UNIVERSITY OF ONTARIO INSTITUTE OF TECHNOLOGY   (Canada)

Author keywords

Adjuvants; Immune response; Mucosal vaccines; Nanoparticles

Indexed keywords

ARCHAEOSOME; CHOLERA TOXIN; CHOLERA VACCINE; CYTOKINE; DRUG CARRIER; ENTEROTOXIN; FLT3 LIGAND; IMMUNOLOGICAL ADJUVANT; IMMUNOSTIMULATING AGENT; LIPOSOME; MAST CELL ACTIVATOR; MUCOSAL VACCINE; NANOPARTICLE; PATTERN RECOGNITION RECEPTOR; UNCLASSIFIED DRUG; VACCINE;

ADAPTIVE IMMUNITY; ADJUVANT THERAPY; ANTIGEN PRESENTING CELL; CELLULAR IMMUNITY; CYTOKINE PRODUCTION; DRUG DELIVERY SYSTEM; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOGENICITY; INNATE IMMUNITY; MAST CELL; MUCOSAL IMMUNITY; NANOEMULSION; NONHUMAN; PATTERN RECOGNITION; PRIORITY JOURNAL; REVIEW; VIRUS LIKE AGENT; IMMUNOLOGY; MEDICAL RESEARCH; MUCOSAL DRUG ADMINISTRATION; TRENDS;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, MUCOSAL; BIOMEDICAL RESEARCH; HUMANS; VACCINES;

EID: 84928581450     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2015.03.096     Document Type: Review

References (69)

1. McGhee J.R. A mucosal gateway for vaccines. Nat Biotechnol 2011, 29(2):136-138.
2. McGhee J.R., Mestecky J., Dertzbaugh M.T., Eldridge J.H., Hirasawa M., Kiyono H. The mucosal immune system: from fundamental concepts to vaccine development. Vaccine 1992, 10(2):75-88.
3. Azizi A., Kumar A., Diaz-Mitoma F., Mestecky J. Enhancing oral vaccine potency by targeting intestinal M cells. PLoS Pathog 2010, 6(11):e1001147.
4. Azizi A., Ghunaim H., Diaz-Mitoma F., Mestecky J. Mucosal HIV vaccines: a holy grail or a dud?. Vaccine 2010, 28(May (24)):4015-4026.
5. Ghunaim H., Kumar A., Torres J., Diaz-Mitoma F., Azizi A. An immunological comparison between lipidated and non-lipidated multivalent HIV-1 peptides representing Gp120 and Gag hypervariable regions. Vaccine 2011, 29(Aug (35)):5950-5958.
6. Hasegawa H., van Reit E., Kida H. Mucosal immunization and adjuvants. Curr Top Microbiol Immunol 2015, 386:371-380. Review.
7. Mohan T., Verma P., Rao D.N. Novel adjuvants & delivery vehicles for vaccines development: a road ahead. Indian J Med Res 2013, 138(Nov (5)):779-795.
8. Schmidt C.S., Morrow W.J., Sheikh N.A. Smart adjuvants. Expert Rev Vaccines 2007, 6(Jun (3)):391-400.
9. Holmgren J., Czerkinsky C., Eriksson K., Mharandi A. Mucosal immunisation and adjuvants: a brief overview of recent advances and challenges. Vaccine 2003, 21(Jun (Suppl 2)):S89-S95.
10. Negri D.R., Pinto D., Vendetti S., et al. Cholera toxin and Escherichia coli heat-labile enterotoxin, but not their nontoxic counterparts, improve the antigen-presenting cell function of human B lymphocytes. Infect Immun 2009, 77(5):1924-1935.
11. Anosova N.G., Chabot S., Shreedhar V., Borawski J.A., Dickinson B.L., Neutra M.R. Cholera toxin, E. coli heat-labile toxin, and non-toxic derivatives induce dendritic cell migration into the follicle-associated epithelium of Peyer's patches. Mucosal Immunol 2008, 1(1):59-67.
12. Pizza M., Giuliani M.M., Fontana M.R., et al. Mucosal vaccines: non toxic derivatives of LT and CT as mucosal adjuvants. Vaccine 2001, 19(Mar (17-19)):2534-2541.
13. Sjokvist O.L., Flach C.F., Clements J., Holmgren J., Raghavan S. A double mutant heat-labile toxin from Escherichia coli, LT(R192G/L211A), is an effective mucosal adjuvant for vaccination against Helicobacter pylori infection. Infect Immun 2013, 81(5):1532-1540.
14. Mutsch M., Zhou W., Rhodes P., et al. Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland. N Engl J Med 2004, 350(Feb (9)):896-903.
15. Lewis D.J., Huo Z., Barnett S., et al. Transient facial nerve paralysis (Bell's palsy) following intranasal delivery of a genetically detoxified mutant of Escherichia coli heat labile toxin. PLoS ONE 2009, 4(9):e6999.
16. van Ginkel F.W., Jackson R.J., Yuki Y., McGhee J.R. Cutting edge: the mucosal adjuvant cholera toxin redirects vaccine proteins into olfactory tissues. J Immunol 2000, 165(Nov (9)):4778-4782.
17. van Ginkel F.W., Jackson R.J., Yoshino N., et al. Enterotoxin-based mucosal adjuvants alter antigen trafficking and induce inflammatory responses in the nasal tract. Infect Immun 2005, 73(10):6892-6902.
18. da Hora V.P., Conceicao F.R., Dellagostin O.A., Doolan D.L. Non-toxic derivatives of LT as potent adjuvants. Vaccine 2011, 29(Feb (8)):1538-1544.
19. Brynjolfsson S.F., Bjarnarson S.P., Mori E., Del G.G., Jonsdottir I. Neonatal immune response and serum bactericidal activity induced by a meningococcal conjugate vaccine is enhanced by LT-K63 and CpG2006. Vaccine 2008, 26(Aug (35)):4557-4562.
20. Barrette R.W., Szczepanek S.M., Rood D., et al. Use of inactivated Escherichia coli enterotoxins to enhance respiratory mucosal adjuvanticity during vaccination in swine. Clin Vaccine Immunol 2011, 18(11):1996-1998.
21. Nedrud J.G., Bagheri N., Schon K., et al. Subcomponent vaccine based on CTA1-DD adjuvant with incorporated UreB class II peptides stimulates protective Helicobacter pylori immunity. PLoS ONE 2013, 8(12):e83321.
22. Eliasson D.G., Helgeby A., Schon K., et al. A novel non-toxic combined CTA1-DD and ISCOMS adjuvant vector for effective mucosal immunization against influenza virus. Vaccine 2011, 29(May (23)):3951-3961.
23. Maisonneuve C., Bertholet S., Philpott D.J., De G.E. Unleashing the potential of NOD- and Toll-like agonists as vaccine adjuvants. Proc Natl Acad Sci USA 2014, 111(Aug (34)):12294-12299.
24. Rhee J.H., Lee S.E., Kim S.Y. Mucosal vaccine adjuvants update. Clin Exp Vaccine Res 2012, 1(Jul (1)):50-63.
25. Keler T., Ramakrishna V., Fanger M.W. Mannose receptor-targeted vaccines. Expert Opin Biol Ther 2004, 4(12):1953-1962.
26. Kawasaki T., Kawai T. Toll-like receptor signaling pathways. Front Immunol 2014, 5:461.
27. McClure R., Massari P. TLR-dependent human mucosal epithelial cell responses to microbial pathogens. Front Immunol 2014, 5:386.
28. Zeytun A., Chaudhary A., Pardington P., Cary R., Gupta G. Induction of cytokines and chemokines by Toll-like receptor signaling: strategies for control of inflammation. Crit Rev Immunol 2010, 30(1):53-67.
29. Hirano T., Kodama S., Moriyama M., Kawano T., Suzuki M. The role of Toll-like receptor 4 in eliciting acquired immune responses against nontypeable Haemophilus influenzae following intranasal immunization with outer membrane protein. Int J Pediatr Otorhinolaryngol 2009, 73(12):1657-1665.
30. Domingos-Pereira S., Decrausaz L., Derre L., et al. Intravaginal TLR agonists increase local vaccine-specific CD8 T cells and human papillomavirus-associated genital-tumor regression in mice. Mucosal Immunol 2013, 6(Mar (2)):393-404.
31. Hjelm B.E., Kilbourne J., Herbst-Kralovetz M.M. TLR7 and 9 agonists are highly effective mucosal adjuvants for norovirus virus-like particle vaccines. Hum Vaccin Immunother 2014, 10(2):410-416.
32. Buffa V., Klein K., Fischetti L., Shattock R.J. Evaluation of TLR agonists as potential mucosal adjuvants for HIV gp140 and tetanus toxoid in mice. PLoS ONE 2012, 7(12):e50529.
33. Evans T.G., Hasan M., Galibert L., Caron D. The use of Flt3 ligand as an adjuvant for hepatitis B vaccination of healthy adults. Vaccine 2002, 21(Dec (3-4)):322-329.
34. Fukuyama Y., King J.D., Kataoka K., et al. A combination of Flt3 ligand cDNA and CpG oligodeoxynucleotide as nasal adjuvant elicits protective secretory-IgA immunity to Streptococcus pneumoniae in aged mice. J Immunol 2011, 186(Feb (4)):2454-2461.
35. Kayamuro H., Yoshioka Y., Abe Y., et al. Interleukin-1 family cytokines as mucosal vaccine adjuvants for induction of protective immunity against influenza virus. J Virol 2010, 84(Dec (24)):12703-12712.
36. Bradney C.P., Sempowski G.D., Liao H.X., Haynes B.F., Staats H.F. Cytokines as adjuvants for the induction of anti-human immunodeficiency virus peptide immunoglobulin G (IgG) and IgA antibodies in serum and mucosal secretions after nasal immunization. J Virol 2002, 76(Jan (2)):517-524.
37. Khan T., Heffron C.L., High K.P., Roberts P.C. Membrane-bound IL-12 and IL-23 serve as potent mucosal adjuvants when co-presented on whole inactivated influenza vaccines. Virol J 2014, 11:78.
38. Huber V.C., Arulanandam B.P., Arnaboldi P.M., et al. Delivery of IL-12 intranasally leads to reduced IL-12-mediated toxicity. Int Immunopharmacol 2003, 3(6):801-809.
39. Car B.D., Eng V.M., Lipman J.M., Anderson T.D. The toxicology of interleukin-12: a review. Toxicol Pathol 1999, 27(1):58-63.
40. Leonard J.P., Sherman M.L., Fisher G.L., et al. Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production. Blood 1997, 90(Oct (7)):2541-2548.
41. Cohen J. IL-12 deaths: explanation and a puzzle. Science 1995, 270(Nov (5238)):908.
42. van Herpen C.M., Bussink J., van der Kogel A.J., et al. Interleukin-12 has no effect on vascular density, perfusion, hypoxia and proliferation of an implanted human squamous cell carcinoma xenograft tumour despite up-regulation of ICAM-1. Anticancer Res 2005, 25(Mar (2A)):1015-1021.
43. van Herpen C.M., van der Laak J.A., de Vries I.J., et al. Intratumoral recombinant human interleukin-12 administration in head and neck squamous cell carcinoma patients modifies locoregional lymph node architecture and induces natural killer cell infiltration in the primary tumor. Clin Cancer Res 2005, 11(Mar (5)):1899-1909.
44. van Herpen C.M., van der Voort R., van der Laak J.A., et al. Intratumoral rhIL-12 administration in head and neck squamous cell carcinoma patients induces B cell activation. Int J Cancer 2008, 123(Nov (10)):2354-2361.
45. McLachlan J.B., Shelburne C.P., Hart J.P., et al. Mast cell activators: a new class of highly effective vaccine adjuvants. Nat Med 2008, 14(5):536-541.
46. Meng S., Liu Z., Xu L., et al. Intranasal immunization with recombinant HA and mast cell activator C48/80 elicits protective immunity against 2009 pandemic H1N1 influenza in mice. PLoS ONE 2011, 6(5):e19863.
47. Xu L., Bao L., Li F., et al. Intranasal immunization of mice with inactivated virus and mast cell activator C48/80 elicits protective immunity against influenza H1 but not H5. Immunol Invest 2014, 43(3):224-235.
48. Gregory A.E., Titball R., Williamson D. Vaccine delivery using nanoparticles. Front Cell Infect Microbiol 2013, 3:13.
49. Pattenden L.K., Middelberg A.P., Niebert M., Lipin D.I. Towards the preparative and large-scale precision manufacture of virus-like particles. Trends Biotechnol 2005, 23(10):523-529.
50. Zeltins A. Construction and characterization of virus-like particles: a review. Mol Biotechnol 2013, 53(1):92-107.
51. Jennings G.T., Bachmann M.F. Immunodrugs: therapeutic VLP-based vaccines for chronic diseases. Annu Rev Pharmacol Toxicol 2009, 49:303-326.
52. Woodrow K.A., Bennett K.M., Lo D.D. Mucosal vaccine design and delivery. Annu Rev Biomed Eng 2012, 14:17-46.
53. Vassilieva E.V., Wang B.Z., Vzorov A.N., et al. Enhanced mucosal immune responses to HIV virus-like particles containing a membrane-anchored adjuvant. MBio 2011, 2(1):e00328-e410.
54. Wang B.Z., Gill H.S., Kang S.M., et al. Enhanced influenza virus-like particle vaccines containing the extracellular domain of matrix protein 2 and a Toll-like receptor ligand. Clin Vaccine Immunol 2012, 19(8):1119-1125.
55. Heurtault B., Frisch B., Pons F. Liposomes as delivery systems for nasal vaccination: strategies and outcomes. Expert Opin Drug Deliv 2010, 7(7):829-844.
56. Henriksen-Lacey M., Korsholm K.S., Andersen P., Perrie Y., Christensen D. Liposomal vaccine delivery systems. Expert Opin Drug Deliv 2011, 8(4):505-519.
57. Christensen D., Foged C., Rosenkrands I., et al. CAF01 liposomes as a mucosal vaccine adjuvant: In vitro and in vivo investigations. Int J Pharm 2010, 390(May (1)):19-24.
58. Henderson A., Propst K., Kedl R., Dow S. Mucosal immunization with liposome-nucleic acid adjuvants generates effective humoral and cellular immunity. Vaccine 2011, 29(Jul (32)):5304-5312.
59. Patel G.B., Chen W. Archaeosome immunostimulatory vaccine delivery system. Curr Drug Deliv 2005, 2(Oct (4)):407-421.
60. Schwendener R.A. Liposomes as vaccine delivery systems: a review of the recent advances. Ther Adv Vaccines 2014, 2(Nov (6)):159-182.
61. Li Z., Zhang L., Sun W., Ding Q., Hou Y., Xu Y. Archaeosomes with encapsulated antigens for oral vaccine delivery. Vaccine 2011, 29(Jul (32)):5260-5266.
62. Patel G.B., Zhou H., Ponce A., Harris G., Chen W. Intranasal immunization with an archaeal lipid mucosal vaccine adjuvant and delivery formulation protects against a respiratory pathogen challenge. PLoS ONE 2010, 5(12):e15574.
63. Nochi T., Yuki Y., Takahashi H., et al. Nanogel antigenic protein-delivery system for adjuvant-free intranasal vaccines. Nat Mater 2010, 9(7):572-578.
64. Kong I.G., Sato A., Yuki Y., et al. Nanogel-based PspA intranasal vaccine prevents invasive disease and nasal colonization by Streptococcus pneumoniae. Infect Immun 2013, 81(5):1625-1634.
65. Das S.C., Hatta M., Wilker P.R., et al. Nanoemulsion W805EC improves immune responses upon intranasal delivery of an inactivated pandemic H1N1 influenza vaccine. Vaccine 2012, 30(Nov (48)):6871-6877.
66. Brito L.A., Chan M., Shaw C.A., et al. A cationic nanoemulsion for the delivery of next-generation RNA vaccines. Mol Ther 2014, 22(12):2118-2129.
67. Bielinska A.U., Makidon P.E., Janczak K.W., et al. Distinct pathways of humoral and cellular immunity induced with the mucosal administration of a nanoemulsion adjuvant. J Immunol 2014, 192(Mar (6)):2722-2733.
68. Stanberry L.R., Simon J.K., Johnson C., et al. Safety and immunogenicity of a novel nanoemulsion mucosal adjuvant W805EC combined with approved seasonal influenza antigens. Vaccine 2012, 30(Jan (2)):307-316.
69. Azizi A., Ghunaim H., Sirskyj D., Fallahi F., Le H.T., Kumar A. Delivery of immunogens to mucosal immune system using an oral inactivated cholera vaccine: a new approach for development of oral vaccines. Hum Vaccin Immunother 2013, 9(7):1445-1448.